Aβ peptides as one of the crucial volume transmission signals in the trophic units and their interactions with homocysteine.: Physiological implications and relevance for Alzheimer's disease

被引:35
作者
Agnati, L. F.
Genedani, S.
Leo, G.
Forni, A.
Woods, A. S.
Filaferro, M.
Franco, R.
Fuxe, K.
机构
[1] Univ Modena & Reggio Emilia, Physiol Sect, Dept Biomed Sci, I-41100 Modena, Italy
[2] Univ Modena & Reggio Emilia, Pharmacol Sect, Dept Biomed Sci, I-41100 Modena, Italy
[3] Univ Modena & Reggio Emilia, Dept Chem, I-41100 Modena, Italy
[4] IRCCS San Camillo, Venice, Italy
[5] Natl Inst Drug Abuse, Dept Hlth & Human Serv, Baltimore, MD USA
[6] Univ Barcelona, Dept Biochem & Mol Biol, Barcelona, Spain
[7] Karolinska Inst, Dept Neurosci, Stockholm, Sweden
关键词
beta-amyloid peptides; homocysteine; volume transmission; pain threshold; Alzheimer's disease;
D O I
10.1007/s00702-006-0564-9
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Amyloid peptides (A beta) can operate as volume transmission (VT) signals since they are continuously released from cells of the central nervous system and diffuse in the extra-cellular space of the brain. They have both regulatory and trophic functions on cellular networks. In agreement with A beta regulatory actions on glial-neuronal networks, the present paper reports new findings demonstrating that intrastriatal injections of A beta peptides reduce striatal tyrosine hydroxylase, increase striatal GFAP immunoreactivities and lower pain threshold in experimental rats. Furthermore, it has been demonstrated that exogenous homocysteine (Hcy) binds A beta(1-40) favouring its beta-sheet conformation both in vitro and in vivo and hence the formation of beta-fibrils and development of neurotoxicity. Thus, the hypothesis is discussed that A beta peptides represent crucial VT-signals in the brain and their action is altered by dysmetabolic signals such as high Hcy extra-cellular levels, known to be an important risk factor for Alzheimer's disease.
引用
收藏
页码:21 / 31
页数:11
相关论文
共 50 条
  • [1] THE CONCEPT OF TROPHIC UNITS IN THE CENTRAL-NERVOUS-SYSTEM
    AGNATI, LF
    CORTELLI, P
    PETTERSSON, R
    FUXE, K
    [J]. PROGRESS IN NEUROBIOLOGY, 1995, 46 (06) : 561 - 574
  • [2] Agnati LF, 2000, PROG BRAIN RES, V125, P3
  • [3] Neuroprotective effect of L-DOPA co-administered with the adenosine A2A receptor agonist CGS 21680 in an animal model of Parkinson's disease
    Agnati, LF
    Leo, G
    Vergoni, AV
    Martínez, E
    Hockemeyer, J
    Lluis, C
    Franco, R
    Fuxe, K
    Ferré, S
    [J]. BRAIN RESEARCH BULLETIN, 2004, 64 (02) : 155 - 164
  • [4] Studies on homocysteine plasma levels in Alzheimer's patients.: Relevance for neurodegeneration
    Agnati, LF
    Genedani, S
    Rasio, G
    Galantucci, M
    Saltini, S
    Filaferro, M
    Franco, R
    Mora, F
    Ferré, S
    Fuxe, K
    [J]. JOURNAL OF NEURAL TRANSMISSION, 2005, 112 (01) : 163 - 169
  • [5] AGNATI LF, 1986, IMMUNOCYTOCHEMISTRY, P205
  • [6] AGNATI LF, 1985, QUANTITATIVE NEUROAN, P91
  • [7] The role of dopamine in the nucleus accumbens in analgesia
    Altier, N
    Stewart, J
    [J]. LIFE SCIENCES, 1999, 65 (22) : 2269 - 2287
  • [8] [Anonymous], 1998, Practical nonparametric statistics
  • [9] Amyloid-β:: a chameleon walking in two worlds:: a review of the trophic and toxic properties of amyloid-β
    Atwood, CS
    Obrenovich, ME
    Liu, TB
    Chan, H
    Perry, G
    Smith, MA
    Martins, RN
    [J]. BRAIN RESEARCH REVIEWS, 2003, 43 (01) : 1 - 16
  • [10] Parallel "pain" pathways arise from subpopulation of primary afferent nociceptor
    Braz, JM
    Nassar, MA
    Wood, JN
    Basbaum, AI
    [J]. NEURON, 2005, 47 (06) : 787 - 793